Actively Recruiting

Phase Not Applicable
Age: 55Years - 80Years
All Genders
NCT06385106

Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-05-11

30

Participants Needed

1

Research Sites

93 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Previous studies have shown that repetitive transcranial magnetic stimulation (rTMS) can improve cognitive function in Alzheimer's disease (AD), but studies on the improvement of sleep disorders in AD are limited. The aim of this study was to evaluate the effects of rTMS on sleep and cognition in patients with mild-to-moderate Alzheimer's disease (AD).

CONDITIONS

Official Title

Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Who Can Participate

Age: 55Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant meets 2014 IWG-2 criteria for hippocampal amnestic syndrome typical of Alzheimer's disease with progressive episodic memory impairment confirmed by neuropsychology
  • Cerebrospinal fluid markers or AV-45 PET imaging consistent with Alzheimer's disease pathophysiology
  • Aged between 55 and 80 years
  • No visual or hearing impairment
  • Right-handed
  • Han nationality
  • Signed informed consent
  • Has reliable caregivers to provide information
  • MMSE score between 10 and 27; Clinical Dementia Rating (CDR) between 0.5 and 2 points
  • If on approved Alzheimer's disease treatment, dose must be stable for at least 3 months prior and unchanged unless medically necessary
Not Eligible

You will not qualify if you...

  • History of seizures or epilepsy diagnosis
  • History of stroke
  • Nervous system diseases causing brain dysfunction such as schizophrenia, severe anxiety or depression, dementia other than Alzheimer's, Huntington's disease, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, or hydrocephalus
  • Severe liver, kidney, or lung dysfunction; anemia; gastrointestinal diseases; arrhythmia; recent myocardial infarction
  • Use of barbiturates or benzodiazepines within 2 weeks
  • Contraindications to MRI or TMS such as metallic implants
  • Systemic diseases causing cognitive impairment including hypothyroidism, folate or vitamin B12 deficiency, infections, alcohol or drug abuse
  • Aphasia, consciousness disturbances, or inability to cooperate
  • Previous treatment with TMS, transcranial direct current stimulation, or deep brain stimulation
  • Underlying pathology other than Alzheimer's disease
  • Focal brain lesions on MRI T1/T2 images
  • Refusal to sign informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China, 310003

Actively Recruiting

Loading map...

Research Team

G

Guoping Peng, Doctor

CONTACT

X

Xiaoyan Liu, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here